Flavio Solca
- Oncology top 1%
- HER2/EGFR in Cancer Research 32
- Lung Cancer Research Studies 10
- Colorectal Cancer Treatments and Studies 9
- Peptidase Inhibition and Analysis 7
-
- Lung Cancer Treatments and Mutations 50
- Molecular Biology top 5%
- PI3K/AKT/mTOR signaling in cancer 10
- Cancer Research top 5%
- Otorhinolaryngology top 5%
-
- Monoclonal and Polyclonal Antibodies Research 9
-
- Chronic Lymphocytic Leukemia Research 6
Flavio Solca
84 papers receiving 3.8k citations
Hit Papers
Peers
Comparison fields: 5 of 103
- Oncology 2.3k
- Pulmonary and Respiratory Medicine 2.0k
- Molecular Biology 1.8k
- Cancer Research 382
- Otorhinolaryngology 82
Countries citing papers authored by Flavio Solca
This map shows the geographic impact of Flavio Solca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Flavio Solca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Flavio Solca more than expected).
Fields of papers citing papers by Flavio Solca
This network shows the impact of papers produced by Flavio Solca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Flavio Solca. The network helps show where Flavio Solca may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Flavio Solca, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 5 | |
| 2 | 2024 | 10 | |
| 3 | 2023 | 3 | |
| 4 | 2022 | 2 | |
| 5 | 2022 | 22 | |
| 6 | 2020 | 14 | |
| 7 | 2019 | 3 | |
| 8 | 2017 | 9 | |
| 9 | 2016 | 28 | |
| 10 | 2016 | 4 | |
| 11 | 2016 | 1 | |
| 12 | 2016 | 23 | |
| 13 | 2015 | 1 | |
| 14 | 2015 | 22 | |
| 15 | 2013 | 81 | |
| 16 | 2012 | 172 | |
| 17 | Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blockerbreakdown → | 2012 | 684 |
| 18 | 2011 | 64 | |
| 19 | 2007 | 8 | |
| 20 | 1993 | 21 |
About Flavio Solca
Flavio Solca is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology, having authored 85 papers that have together received 3.8k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (50 papers), HER2/EGFR in Cancer Research (32 papers), PI3K/AKT/mTOR signaling in cancer (10 papers), Lung Cancer Research Studies (10 papers), Monoclonal and Polyclonal Antibodies Research (9 papers), Colorectal Cancer Treatments and Studies (9 papers), Peptidase Inhibition and Analysis (7 papers) and Chronic Lymphocytic Leukemia Research (6 papers). The work is most often cited by research in Oncology (2.3k citations), Pulmonary and Respiratory Medicine (2.0k citations) and Molecular Biology (1.8k citations). Flavio Solca has collaborated with scholars based in Austria, Germany and United States. Frequent co-authors include Frank Himmelsbach, Anke Baum, Heidi Greulich, Takeshi Shimamura, Wolfgang J. Rettig, Lucian R. Chirieac, Kah Keng Wong, Robert F. Padera, Masaya Takahashi and Shigeto Kubo. Their work appears in journals such as Annals of Oncology, Cancer Research, European Journal of Cancer, Journal of Clinical Oncology and Molecular Cancer Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.